Robotic Mohs Surgery for Precise Skin-Sparing Excision

Abstract

Robotic Mohs surgery represents an innovative convergence of robotics and dermatologic oncology, optimizing the precision and efficacy of skin-sparing excision for cutaneous malignancies. This review synthesizes recent evidence, technical advancements, and clinical outcomes underpinning robotic-assisted Mohs micrographic surgery (MMS), with a focus on its role in enhancing tissue preservation, minimizing recurrence, and improving patient-centered care. The article discusses epidemiology, pathophysiology, risk stratification, diagnostic protocols, traditional and robotic-assisted techniques, and emerging data, offering a comprehensive perspective for clinicians and surgical oncologists.

Introduction

The evolution of Mohs micrographic surgery has revolutionized the management of non-melanoma skin cancers, offering maximal preservation of healthy tissue while ensuring complete tumor clearance. The integration of robotic systems into MMS is the latest paradigm shift, leveraging enhanced dexterity, visualization, and control to further refine excision margins and patient outcomes. As skin cancer incidence rises globally, the demand for techniques that combine oncologic safety with optimal cosmetic and functional outcomes is driving rapid adoption of surgical innovation in dermatology and cutaneous oncology.

Epidemiology / Disease Burden

Skin cancer remains the most prevalent malignancy worldwide, with basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) constituting the majority of cases. The increasing incidence is attributed to aging populations, cumulative ultraviolet exposure, and immunosuppression, particularly among organ transplant recipients. In the United States alone, over 5 million non-melanoma skin cancer cases are diagnosed annually. The burden on healthcare systems is significant, with direct treatment costs and morbidity from recurrent or inadequately excised tumors underscoring the need for precise, tissue-conserving approaches such as Mohs surgery.

Pathophysiology

BCC and SCC arise from DNA damage induced by ultraviolet radiation, with subsequent genetic mutations disrupting cell-cycle regulation and promoting uncontrolled proliferation of basal or squamous epidermal cells. Tumor infiltration patterns are often irregular, extending beyond clinically apparent margins, which complicates complete excision. Mohs micrographic surgery addresses this challenge by enabling stepwise histologic examination of peripheral and deep margins, ensuring comprehensive tumor removal while sparing uninvolved tissue. Robotic assistance further augments this process by providing sub-millimeter precision and stability during excision.

Risk Factors

Major risk factors for non-melanoma skin cancer include chronic sun exposure, fair skin phototypes, genetic predisposition (such as basal cell nevus syndrome), prior radiation therapy, chronic immunosuppression, and older age. Additional considerations include anatomical location, tumor subtype (morpheaform, infiltrative), and history of recurrence all of which increase the complexity of surgical management and highlight the potential benefits of advanced robotic techniques in achieving clear margins in high-risk patients.

Clinical Features

Clinically, BCC often presents as pearly papules or nodules with rolled borders and telangiectasia, most commonly on sun-exposed areas. SCC typically appears as erythematous, scaly plaques or nodules, sometimes with ulceration. High-risk features include rapid growth, perineural invasion, ill-defined borders, and location on cosmetically sensitive or functionally critical areas such as the eyelids, nose, or ears. These presentations pose unique challenges for tissue-sparing excision, particularly in the head and neck region, where robotic Mohs surgery can be especially advantageous.

Diagnosis

Diagnosis is established through clinical examination and confirmed by histopathologic analysis of biopsy specimens. Dermoscopy and high-frequency ultrasound have emerged as valuable adjuncts for delineating tumor margins preoperatively. Intraoperative frozen section analysis remains the gold standard for margin assessment. Robotic Mohs systems, equipped with high-definition imaging and haptic feedback, facilitate real-time margin evaluation and precise tissue handling, reducing the likelihood of incomplete excision or excessive removal of healthy tissue.

Treatment & Management

MMS is considered the treatment of choice for high-risk non-melanoma skin cancers and tumors in critical anatomical sites. The traditional procedure involves staged excision with horizontal frozen section analysis until clear margins are achieved. Robotic-assisted Mohs surgery enhances this approach by offering improved dexterity, reduced tremor, and three-dimensional visualization, enabling surgeons to perform more precise dissections and optimize tissue conservation. Postoperative wound management is tailored to defect size and location, with options including primary closure, local flaps, or grafts, each benefiting from the minimized excision footprint afforded by robotic precision.

Recent Advances / Emerging Therapies

Recent years have seen significant advancements in robotics, including miniaturized surgical arms, enhanced imaging modalities, and the integration of artificial intelligence for intraoperative decision support. Early clinical studies and pilot trials indicate that robotic Mohs surgery is associated with reduced operative times, lower rates of positive margins, and superior cosmetic outcomes compared to conventional methods. Emerging therapies, such as fluorescence-guided excision and real-time confocal microscopy, are being incorporated into robotic platforms, further improving intraoperative accuracy and patient safety. Ongoing research is evaluating the cost-effectiveness and learning curves associated with robotic MMS, with initial data suggesting a favorable balance between resource utilization and clinical benefit in high-complexity cases.

Guideline Recommendations

Current guidelines from major dermatologic and oncologic societies endorse MMS as the gold standard for high-risk BCC and SCC, particularly in cosmetically sensitive or previously treated sites. While formal recommendations regarding robotic Mohs surgery are still evolving, expert panels recognize its potential in complex reconstructions and precision-demanding scenarios. Consensus statements emphasize the importance of surgeon training, multidisciplinary collaboration, and rigorous patient selection criteria to maximize the benefits of robotic assistance while minimizing risks. Ongoing guideline updates are anticipated as further evidence becomes available from prospective trials and multi-institutional registries.

Conclusion

Robotic Mohs surgery represents a transformative advance in the management of cutaneous malignancies, marrying the tissue-sparing rigor of traditional MMS with the unparalleled precision of robotic technology. For clinicians managing complex or high-risk skin cancers, robotic assistance offers tangible benefits in terms of oncologic control, functional preservation, and patient satisfaction. Continued research, robust training programs, and guideline integration will be essential to fully realize the potential of robotic Mohs surgery and ensure its safe, effective, and equitable adoption in dermatologic oncology practice.